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Patients with advanced epithelial ovarian cancer are treated with
extensive cytoreductive surgery followed by several cycles of
aggressive combination chemotherapy. Nevertheless, few patients
stay relapse-free, and the overall prognosis, with a 5-year survival
rate of 20% (Averette et al, 1996), is poor.
Survival probability is influenced by the stage of disease,
residual tumour, histological type and tumour grade (Swenerton
et al, 1985; Krag et al, 1989). In addition, the cancer antigen CA
125 is an established potential useful marker to monitor response
to therapy and for early detection of relapse in patients with
ovarian cancer (Bast et al, 1983). Several studies based on serial
CA 125 measurements have addressed the above mentioned impli-
cations (Canney et al, 1984; Lavin et al, 1987; Rustin et al, 1989;
Sevelda et al, 1989; Redman et al, 1990; Makar et al, 1992;
Yedema et al, 1993a). However, the patient populations in these
studies were either heterogeneous and fairly small in numbers, or
the end points of outcome measurements were different (progres-
sion, response, relapse of patients in remission or survival).
Despite general acceptance that CA 125 is a prognostic marker,
there remains controversy as to how accurately serial CA 125
measurements can predict long-term overall survival in patients
with advanced ovarian cancer.
The objective of the present study was to evaluate the prog-
nostic influence of CA 125 regression between the time point
before surgery and after two completed courses of chemotherapy
on long-term survival. The rationale for the time points used was
that cytoreductive surgery may cause a transient increase in CA
125, which may last for up to 2 weeks (Yedema et al, 1993b), and
therefore prechemotherapy CA 125 sampling shortly after surgery
might not be a reliable baseline parameter. In addition, the
timespan between CA 125 preoperatively (CA 125 pre) and 3
months after surgery (CA 125 3 mo) reflects the effectiveness of
the treatment modalities, which will both have an effect on long-
term survival. The effect of the regression of serum CA 125 levels
as a prognostic factor for overall survival was assessed in a Cox
proportional hazards model in comparison with other established
prognostic factors.
MATERIALS AND METHODS
Two-hundred and ten consecutive patients with International
Federation of Gynaecology and Obstetrics (FIGO) stage III and
IV invasive epithelial ovarian cancers and a survival of at least
3 months after surgery, were included in the present study. Non-
epithelial tumours and borderline ovarian carcinomas as well as
patients with secondary malignancies were excluded. All patients
underwent primary surgery at the University Hospital of Vienna or
the General Hospital Lainz in Vienna from 1984 to 1996. Surgery
was followed by platinum-containing combination chemotherapy;
subsequent courses were administered on a monthly basis. Clinical
staging was performed according to the criteria established by
FIGO (International Federation of Gynaecology and Obstetrics,
1987). Histological classification was based on the criteria defined
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by the World Health Organization (Serov et al, 1973). Grading was
performed as outlined by Day et al (1975) Standard surgical treat-
ment consisted of total abdominal hysterectomy (TAH), bilateral
salpingo-oophorectomy (BSO) and omentectomy. Provided it was
technically possible and if not contraindicated for other reason,
pelvic lymphadenectomy was performed as a part of the staging
procedure in those patients who had undergone cytoreductive
surgery with no residual disease. Due to extensive disease some
patients underwent only exploratory laparotomy. After 6 cycles
of platinum-containing combination chemotherapy, the patients
were followed up on a quarterly basis for the first 3 years, every
6 months for 5 years and annually thereafter. Treatment of
relapsed patients included debulking surgery in few cases; other-
wise polychemotherapy was used according to different study
protocols. Information on follow up was obtained from medical
records and the Austrian Statistical Office where all deaths in
Austria are reported and registered.
Well known prognostic factors influencing survival were evalu-
ated. Tumour stage, tumour grading and residual tumour and
ascites were considered as ordered categorical variables.
Histological types were categorized into three groups. Serous
and unclassified histologies formed one subgroup (n = 158),
endometrioid, clear-cell and undifferentiated types (n = 41)
formed another group, and mucinous types (n = 11) remained a
separate entity. The patients were classified into the age groups
≤ 50 and > 50 years, and the type of surgery was classified as TAH
+ BSO + omentectomy versus exploratory laparotomy.
CA 125 was assayed using a radioimmunoassay (Centocor-
Laboratories, Malvern, PA, USA), according to the manufacturer’s
instructions. CA 125 blood samples were collected preoperatively
(CA 125 pre) and 3 months after surgery (CA 125 3 mo) (at
the beginning of the 3rd cycle of chemotherapy), reflecting the
combined effect of primary surgery and the first two courses of
chemotherapy. The parameter CA 125 regression defined as log10
(CA 125 3 mo/CA 125 pre) was regarded as a further potential
prognostic factor of survival.
Statistical methods
Overall survival time was defined as the period between the date
of CA 125 measurement 3 months after primary surgery (CA 125
3 mo) and death. Survival times of patients still alive were
censored with the last follow-up date. Survival probabilities were
calculated by the product limit method of Kaplan and Meier
(1958). The Cox proportional hazards model (Cox, 1972) was
used to assess the univariate and partial effects of prognostic
factors on survival time. For ordered categorical variables a linear
trend was assumed, since no deviations from linearity could be
detected. Cubic spline functions with five knots were used to
model the interaction of time with log10 (CA 125 3 mo/CA 125
pre) (Hess, 1994).
All reported P-values are results of two-sided tests. A P-value
equal to or less than 5% was considered statistically significant.
The SAS statistical software system (SAS Institute Inc., Cary, NC,
USA) was used for calculations. For spline modelling the SAS
macro of Heinzl and Kaider (1997) was used.
RESULTS
A total of 210 patients with stage III and IV ovarian cancers were
included in the study. The median age of the entire patient popula-
tion was 59.7 years (range 22.1–84.0 years). At the time of
analysis, 142 patients had died due to disease and 68 women were
Table 1 Patient characteristics of 210 women with advanced ovarian
cancer
No. %
Age (years)
≤50 54 25.7
>50 156 74.3
FIGO stage
III 183 87.1
IV 27 12.9
Histology
Serous 145 69.0
Mucinous 11 5.2
Endometrioid 17 8.1
Undifferentiated 20 9.6
Clear-cell 4 1.9
Unclassified 13 6.2
Grade
I 31 14.8
II 69 32.9
III 110 52.3
Residual disease (cm)
No residual disease 48 22.9
<2 57 27.1
2–5 39 18.6
>5 66 31.4
Ascites
No ascites 67 31.9
≤500 ml 51 24.3
>500 ml 92 43.8
Surgery
TAH+BSO+omentectomy 164 78.1
Exploratory laparotomy 46 21.9
CA 125 pre
< 35 U ml–1 18 8.5
<100 U ml–1 41 19.5
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Figure 1 Kaplan–Meier plot: survival according to CA 125 regression.
Curve A with >42% (n = 52) or more of the initial preoperative CA 125 value,
curve B: 42–14% (n = 53), curve C: 14–4% (n = 51) and curve D with less
than 4% (n = 54) of the initial CA 125 value664 C Peters-Engl et al
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still alive. The median overall survival interval for the study popu-
lation from 3 months after surgery was 1.92 years (95% confi-
dence interval (CI) 1.39–2.46). Surviving patients were followed
up for a median of 4.73 years (range 0.93–12.22 years) estimated
from 3 months after surgery. Detailed patient characteristics are
summarized in Table 1. Overall, the median preoperative CA 125
value was 453.2 U ml–1 (range 14.0–19 122.0 U ml–1, interquartile
range 160.7–913.2 U ml–1) versus 30.6 U ml–1 (range 1.0–
Table 2 Survival probability in patients with advanced ovarian cancer (univariate analysis)
Prognostic factor No. Patients who died of Kaplan–Meier 75% Univariate proportional hazard model
disease Quantil (years)
P-value Relative risk 95% confidence interval
Age 0.0001 2.3 1.48–3.4
≤ 50 54 28 2.38
> 50 156 114 0.72
FIGO stage 0.017 1.76 1.11–2.8
III 183 121 0.86
IV 27 21 0.34
Histological type 0.37
Serous, unclassified 158 108 0.77
Mucinous 11 5 1.11 0.53 0.22–1.29
Endometrioid, undiff., clear-cell 41 29 0.69 1.007 0.67–1.52
Tumour grade 0.0001 1.66 1.30–2.1
1 31 11 3.02
2 69 47 0.88
3 110 84 0.65
Residual tumour (cm) 0.0001 1.74 1.49–2.0
No 48 18 2.40
< 2 57 37 0.93
2–5 39 28 0.99
>5 66 59 0.46
Ascites 0.0002 1.45 1.19–1.76
No 67 35 1.20
≤ 500 ml 51 38 0.65
> 500 ml 92 69 0.64
Surgery 0.0001 2.7 1.85–3.9
TAH+BSO+omentectomy 164 100 0.89
Exploratory laparotomy 46 42 0.46
log10 (CA 125 3 mo/CA 125 pre) 0.0001 see Figure 2 see Figure 2
<4% 54 32 1.28
4–14% 51 33 1.07
14–42% 53 37 0.76
> 42% 52 40 0.38
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Figure 2 Plot of hazard ratio of a unit change in log10 (CA 125 3 mo/CA 125
pre) versus time. The results of a time-dependent cubic spline fit (thick solid
line) in a univariate Cox model are shown; 95% pointwise confidence bands
(thick dashes) are added to the spline fit. Two reference lines were drawn to
mark the neutral hazard ratio of 1 (thin solid line) and the result of an
ordinary Cox model ignoring time-dependence (thin dotted line)
100
80
60
40
20
0
12345
A B CD
P=0.9167
Years
S
u
r
v
i
v
a
l
 
(
%
)
6
Patients A 34 22 17 11 8 5
at  B 34 23 17 10 7 4
risk: C 35 24 15 10 6 1
D 34 25 19 15 6 4
Figure 3 Kaplan–Meier plot: Survival according to CA 125 regression of an
‘exhaustion’ analysis: restart the clock for the patients still alive at 1 year
after the second cycle of chemotherapy and regrouping according to
quartiles of the CA 125 regression. Curve A with >30% (n = 34) of the initial
preoperative CA 125 value, curve B: 9–30% (n = 34), curve C: 3–9% (n = 35)
and curve D with less than 3% (n = 34) of the initial CA 125 valueCA 125 in advanced ovarian cancer: prediction of long-term survival 665
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8022.0 U ml–1, interquartile range 16.0 U–158.3 U ml–1) after
surgery and two subsequent completed cycles of platinum
containing chemotherapy respectively.
For descriptive reasons the regression of CA 125 was cate-
gorized into four groups, each with a nearly equal number of
patients: Group A with more than 42% (n = 52) of the initial
preoperative CA 125 value after 3 months, Group B: 14–42%
(n = 53), Group C: 4–14% (n = 51) and group D with less than 4%
(n = 54) of the initial CA 125 value. Survival probabilities
according to Kaplan–Meier are shown in Figure 1.
For the Cox proportional hazards model the regression of CA
125 was defined as log10 (CA 125 3 mo/CA 125 pre). Univariate
analysis identified a number of significant prognostic factors for
survival. The impact of each of the evaluated prognostic factors
is shown in Table 2. Using log10 (CA 125 3 mo/CA 125 pre) as
simple covariate in a univariate Cox model revealed a hazard ratio
of 1.70 (95% CI, 1.32–2.19, P = 0.0001). A more refined analysis
(Hess, 1994) shows that this may be a misleading result. Actually
the effect of log10 (CA 125 3 mo/CA 125 per) on survival is
strongly time-dependent (P = 0.0001, Figure 2). Immediately after
two courses of chemotherapy a hazard ratio of more than 6 (95%
confidence bands shown in Figure 2) was estimated from the data.
Within approximately 1 year, the hazard ratio drops quickly to the
neutral level of 1. These results show that the change in CA 125
3 months after surgery compared to presurgery is an important
prognostic factor. However, its discriminating power is only
temporary. In the first year there is a clear distinction between the
groups, whereas afterwards all surviving patients stay on a
common risk level. Inspecting the Kaplan–Meier survival plot of
an ‘exhaustion’ analysis by starting 12 months into the follow-up
puts emphasis on this finding (Figure 3).
Finally, all prognostic variables were entered as covariates in a
Cox proportional hazards model (Table 3). Of the variables which
showed a significant influence on survival in the univariate
analysis, only CA 125 regression, residual tumour, age and
grading remained as independent variables, whereas stage of
disease, histology, ascites and type of surgery failed to retain
significance. Patients above 50 years of age had a 1.83-fold higher
risk (95% CI 1.16–2.9) of dying from ovarian cancer, while an
increase in tumour grading resulted in a 1.31-fold higher risk (95%
CI 1.008–1.7). The increasing amount of residual tumour corre-
lated significantly with survival (RR 1.59; 95% CI 1.28–1.98).
Mucinous tumours showed a non-significant better prognosis
(RR 0.52). Log10 (CA 125 3 mo/CA 125 pre) shows the same
strong time-dependent effect on survival in the multiple Cox
model (P = 0.0001; data not shown) as in the univariate Cox model
(Figure 2).
DISCUSSION
Aim of this study was to investigate how accurately serial serum
CA 125 measurement can predict long-term survival of patients
with advanced ovarian cancer. This study is one of the largest
series addressing this question with complete data of 210 patients
available for analysis. In the present study CA 125 serum level
regression was, as well as residual tumour, age and tumour grade
an additional independent prognostic factor for survival in patients
with stage III and IV ovarian cancer. Our results show that CA 125
regression from preoperative levels to 3 months after surgery
(including two cycles of chemotherapy) can provide valuable
prognostic information concerning overall survival; however, the
discriminating power of CA 125 for survival seems to be restricted
to the first 12 months.
The phenomenon of CA 125 regression and response to initial
chemotherapy has been well researched and documented by
several authors (Bast et al, 1983; Canney et al, 1984; Lavin et al,
1987; Sevelda et al, 1989; Redman et al, 1990; Mogenson, 1992).
The effect of CA 125 regression is not only important to judge the
patient’s response to cytotoxic chemotherapy but also allows a
distinction between long-term and short-term survivors. In order
to improve the distinction between short-term and long-term
survivors, the patients were divided into four groups according to
their CA 125 regression levels. All groups comprised equal
numbers of patients. Women with a CA 125 regression to less than
4% of the initial baseline value had a median survival of 3.29
years. This should be compared with a median survival of 2.11
years for CA 125 regression between 4% and 14%, and 1.80 years
for CA 125 regression between 14% and 42% respectively.
Survival of patients with tumour marker regression to more than
42% of the baseline values did worst, with a median survival of
0.87 years. The results presented are consistent with findings
obtained by earlier studies on serial CA 125 measurement (Rustin
et al, 1989; Hawkins et al, 1989; Hunter et al, 1990; Fayers et al,
1993; Yedema et al, 1993).
These results may indicate that there might be no point in
continuing cytotoxic chemotherapy in this subset of patients with a
poor long-term prognosis; it might be better to offer them less
toxic, palliative treatment or to randomize them into studies with
Table 3 Results of a multiple proportional hazards model (Cox model)
Prognostic factor P-value Relative risk 95%
Confidence interval
Age 0.0095 1.83 1.16–2.9
FIGO stage 0.40 0.81 0.49–1.33
Histological type 0.33
Serous + unclassified vs mucinous 0.52 0.21–1.29
Serous + unclassified vs endom. + undiff. + clear 1.07 0.70–1.65
Tumour grade 0.044 1.31 1.008–1.7
Residual tumour 0.0001 1.59 1.28–1.98
Ascites 0.32 1.12 0.90–1.41
Surgery 0.89 0.97 0.62–1.53
Log10 (CA 125 3 mo/CA 125 pre) 0.0001 data not shown data not shown666 C Peters-Engl et al
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novel, potentially curative drugs, as suggested by other authors
(Rustin et al, 1989; Sevelda et al, 1989; Mogenson, 1991).
However, this conclusion has to be interpreted with great
caution, because an additional new aspect in the serial CA 125
measurement of advanced ovarian cancer patients was found in
our study when we assessed the interaction of tumour marker
regression with time. Our results show that patients surviving the
critical interval of approximately 1 year will have the same long-
term prognosis that they would have had if they had had a greater
CA 125 fall. A similar conclusion was made by Fayers et al (1993)
showing nearly 20% of the patients in the bad prognostic group to
be alive and progression-free at 12 months. This is in accordance
with our results and further supports our findings.
Nevertheless, two major biases might have effected the interpre-
tation of our data: first, two different phases of CA 125 fall were
included in our measurements, the effect of surgical debulking and
the initial response to chemotherapy. However, the data presented
were highly significant in a multivariate survival analysis
including residual disease as marker for effect of surgery and
tumour reduction. Moreover, the half-life of CA 125 was shown to
be independent on the tumour size at the start of chemotherapy
(Van der Burgh et al, 1988). Secondly, in spite of a good response,
patients with an initially low CA 125 will have a low fall in CA
125 and might be classified in the same group as patients with a
high pre CA 125 and low response which is a general problem
when analysing dynamic processes. We were aware of this fact and
in order to overcome this problem subgroup analysis including
only patients with CA 125 pre > 35 U ml–1 and CA 125 pre
> 100 U ml–1 was performed. Analysis revealed a similar time-
dependent effect of CA 125 regression, confirming the interpreta-
tion of our data (results not shown).
In conclusion, CA 125 regression was an independent prog-
nostic factor for survival in women with advanced ovarian cancer,
and this effect is limited to the duration of 1 year after surgery.
After approximately 1 year, CA 125 did not add information to the
long-term prognosis of these patients. The discriminating power
solely on the basis of serial CA 125 tumor marker levels seems to
be temporary and prediction of individual patients long-term
outcome is not accurate enough.
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